
Two identical pivotal trials evaluating the safety and efficacy of autologous fibroblast therapy (Isolagen Technologies) compared with placebo are almost finished. Special attention was paid in protocol design so there would be consistency across the studies in cell harvesting and injection technique, as well as in outcomes assessments. The treatment protocol, which varies from previous studies, aims to optimize the treatment effect.